Evandro de Azambuja, President of the Belgian Society of Medical Oncology (BSMO) for 2023-2026, shared Jules Bordet Institute‘s post on LinkedIn, adding:
” I had the privilege of working with Prof. Piccart on two landmark trials — HERA and APHINITY.
These pivotal studies in anti-HER2 targeted therapies have saved countless lives worldwide.”
Quoting Jules Bordet Institute’s post:
“A new breakthrough in the fight against breast cancer
The APHINITY study, carried out at the Jules Bordet Institute, is showing promising results for patients.
A step forward, made possible by the power of clinical research and the commitment of the teams of the Brussels University Hospital (H.U.B).
Discover the challenges of research thanks to Prof. Martine Piccart, Scientific Director of the Jules Bordet Institute.”
Proceed to the video attached to the post.
More posts featuring Evandro de Azambuja.